All‐in‐one: The dream and reality of molecular cytopathology testing on routine lung cancer smears

All‐in‐one: The dream and reality of molecular cytopathology testing on routine lung cancer... INTRODUCTIONPersonalized/precision medicine requires the rapid, cost‐effective, and reliable tissue‐based assessment of clinically validated predictive biomarkers. In particular, modern thoracic oncology has deeply transformed the way in which we practice lung cytopathology. The initial perception that cytological samples were merely sufficient for a generic microscopic diagnosis of non‐small cell lung cancer (NSCLC) whereas molecular analysis could only be applied to formalin‐fixed paraffin‐embedded material now has been completely overcome. By coupling microscopy with biomarker characterization, cytology can guide targeted therapy for NSCLC. In individuals with locally advanced or metastatic disease, when patients are not surgical candidates, fine‐needle aspiration biopsy is an ideal minimally invasive approach to inform targeted lung cancer therapy decisions.The study by Guseva et al, published in this issue of Cancer Cytopathology, represents a step ahead to maximize the informativeness of cytological smears. Indeed, treatment paradigms for patients with advanced lung cancer are well established. If the epidermal growth factor receptor (EGFR) gene demonstrates an activating (sensitizing) mutation, the first‐generation tyrosine kinase inhibitors (TKIs) gefitinib (Iressa; AstraZeneca, Cambridge, United Kingdom) and erlotinib (Tarceva; Hoffmann‐La Roche, Basel, Switzerland) or the second‐generation TKI afatinib (Giotrif; Boehringer Ingelheim, Ingelheim, Germany) should be given as first‐line therapy. Similarly, the TKI crizotinib (Xalkori, Pfizer, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Cytopathology Wiley

All‐in‐one: The dream and reality of molecular cytopathology testing on routine lung cancer smears

Loading next page...
 
/lp/wiley/all-in-one-the-dream-and-reality-of-molecular-cytopathology-testing-on-0LXQZg72ee
Publisher
Wiley
Copyright
© 2018 American Cancer Society
ISSN
1934-662X
eISSN
1934-6638
D.O.I.
10.1002/cncy.21962
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONPersonalized/precision medicine requires the rapid, cost‐effective, and reliable tissue‐based assessment of clinically validated predictive biomarkers. In particular, modern thoracic oncology has deeply transformed the way in which we practice lung cytopathology. The initial perception that cytological samples were merely sufficient for a generic microscopic diagnosis of non‐small cell lung cancer (NSCLC) whereas molecular analysis could only be applied to formalin‐fixed paraffin‐embedded material now has been completely overcome. By coupling microscopy with biomarker characterization, cytology can guide targeted therapy for NSCLC. In individuals with locally advanced or metastatic disease, when patients are not surgical candidates, fine‐needle aspiration biopsy is an ideal minimally invasive approach to inform targeted lung cancer therapy decisions.The study by Guseva et al, published in this issue of Cancer Cytopathology, represents a step ahead to maximize the informativeness of cytological smears. Indeed, treatment paradigms for patients with advanced lung cancer are well established. If the epidermal growth factor receptor (EGFR) gene demonstrates an activating (sensitizing) mutation, the first‐generation tyrosine kinase inhibitors (TKIs) gefitinib (Iressa; AstraZeneca, Cambridge, United Kingdom) and erlotinib (Tarceva; Hoffmann‐La Roche, Basel, Switzerland) or the second‐generation TKI afatinib (Giotrif; Boehringer Ingelheim, Ingelheim, Germany) should be given as first‐line therapy. Similarly, the TKI crizotinib (Xalkori, Pfizer,

Journal

Cancer CytopathologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off